<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04248595</url>
  </required_header>
  <id_info>
    <org_study_id>ZDYYGZ201912</org_study_id>
    <nct_id>NCT04248595</nct_id>
  </id_info>
  <brief_title>Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML</brief_title>
  <official_title>Clinical Study of Azacitidine Combined With Homoharringtonie Based Regimens in Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ge Zheng</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongda Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rencent years have witnessed great progress of the treatment of acute myeloid leukemia.&#xD;
      However, most patients have poor outcomes following the currently first-line DA(daunorubicin,&#xD;
      cytarabine)/IA(Idarubicin, cytarabine) chemotherapy, espiecially for the older patients and&#xD;
      those not eligiable for receiving allo-HSCT. Azacitidine (AZA) was listed to methylation of&#xD;
      drugs in China in 2018, is currently the only one approved methylation drugs in the treatment&#xD;
      of AML(acute myeloid leukemia), in the NCCN guidelines. The homoharringtonie could induce&#xD;
      AML(acute myeloid leukemia) cell lines and primary myeloid leukemia cell apoptosis, and the&#xD;
      effect was dose dependent. While, HHT could also induce leukemia cells to differentiate into&#xD;
      normal state, eventually achieve the goal of treatment, and control the disease. The&#xD;
      investigators conducted a clinical study to evaluate the efficacy and safety of the AZA plus&#xD;
      HAG(homoharringtonie, cytarabine, G-CSF), HIA(homoharringtonie, Idarubicin,&#xD;
      cytarabine)/HDA(homoharringtonie, daunorubicin, cytarabine). This study is aimed to validate&#xD;
      the efficacy and safety advantages of the regimens that cotain homoharringtonie and&#xD;
      azacitidine, and to determine which regimen would receive more living benefits.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, the treatment of acute myeloid leukemia still remains a therapeutic challenge.&#xD;
      Patients received traditional chemotherapy have a low remission rate, poor prognosis and&#xD;
      short survival period for patients. New treatment strategies are needed in find out a better&#xD;
      chemotherapy regimen.&#xD;
&#xD;
      Azacitidine (AZA) was listed to methylation of drugs in China in 2018, is currently the only&#xD;
      approved drug for use in acute myeloid leukemia to methylation of drugs, in the NCCN&#xD;
      guidelines. New combinations based on the azacitidine are currently undergoing, and the&#xD;
      preliminary results brought new hope to the treatment of AML.&#xD;
&#xD;
      The homoharringtonie was extracted from tricuspid plants of China. As a protein synthesis&#xD;
      inhibitor, homoharringtonie plays a major role in the G1 / G2 phase in cells. In addition, it&#xD;
      could induce AML cell lines and primary myeloid leukemia cell apoptosis, and the effect was&#xD;
      dose dependent. Meanwhile it could also induce leukemia cells to differentiate into normal&#xD;
      state, eventually controlled the progression of the disease.&#xD;
&#xD;
      Combination with azacitidine may become a new option.This study intends to apply azacitidine&#xD;
      in combination with homoharringtonie for treating AML patients, aiming to improve the&#xD;
      efficacy, reducing adverse reactions and improve the living qualities of patients.&#xD;
&#xD;
      Patients of denovo or relapsed AML(age≥60y) will receive AZA+HAG (homoharringtonie,&#xD;
      cytarabine, G-CSF) regiment as induction therapy. After complete remission(CR), maintenance&#xD;
      therapy with AZA+lenalidomide/AZA will be used every 4-6 weeks until progression or total of&#xD;
      12cycles.&#xD;
&#xD;
      Patients of denovo or relapsed AML(age&lt;60y) will receive AZA +HIA(homoharringtonie,&#xD;
      Idarubicin, cytarabine) or AZA+HDA(homoharringtonie, daunorubicin, cytarabine) regiments as&#xD;
      introduction therapy., After CR, post-remission therapy will follow with NCCN guidelines.&#xD;
&#xD;
      The investigators choose historical AML patients receiving tranditional chemotherapy as a&#xD;
      control group, to validate the efficacy and safety profiles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CR</measure>
    <time_frame>From date of randomization or initial treatment until the date of first documented disease relapse from any cause，assessed up to 100 weeks.</time_frame>
    <description>CR in months, in present of complete remission rate of all participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>From date of randomization or complete remission until the date of first documented disease progression from any cause，assessed up to 100weeks.</time_frame>
    <description>PFS in months, in present of progression free survival period of all participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>From date of randomization until the date of first documented death from any cause or end of this study, whichever come first，assessed up to 100weeks.</time_frame>
    <description>OS in months, in present of over all survival period of all participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events rates</measure>
    <time_frame>From date of randomization or initial treatment until the end date of the study, assessed up to 100 weeks.</time_frame>
    <description>Adverse events rates in percetage.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Azacitidine plus HAG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients of denovo or relapsed AML(age≥60y) will receive AZA+HAG (homoharringtonie, cytarabine, G-CSF) regiment as induction therapy. After complete remission(CR), maintenance therapy with AZA+lenalidomide/AZA will be used every 4-6 weeks until progression or total of 12cycles.&#xD;
AZA -Azacitidine HAG -Homoharringtonie, Cytarabine, G-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azacitidine plus HIA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients of denovo or relapsed AML(age&lt;60y) will receive AZA +HIA(homoharringtonie, Idarubicin, cytarabine) regiments as introduction therapy., After CR, post-remission therapy will follow with NCCN guidelines.&#xD;
AZA -Azacitidine HIA -Homoharringtonie, Cytarabine, Idarubicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azacitidine plus HDA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients of denovo or relapsed AML(age&lt;60y) will receive AZA +HDA(homoharringtonie, daunorubicin, cytarabine) regiments as introduction therapy., After CR, post-remission therapy will follow with NCCN guidelines.&#xD;
AZA -Azacitidine HIA -Homoharringtonie, Cytarabine, Daunorubicin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Homoharringtonine</intervention_name>
    <description>De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.</description>
    <arm_group_label>Azacitidine plus HAG</arm_group_label>
    <arm_group_label>Azacitidine plus HDA</arm_group_label>
    <arm_group_label>Azacitidine plus HIA</arm_group_label>
    <other_name>HHT, Omacetaxine mepesuccinate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.</description>
    <arm_group_label>Azacitidine plus HAG</arm_group_label>
    <arm_group_label>Azacitidine plus HDA</arm_group_label>
    <arm_group_label>Azacitidine plus HIA</arm_group_label>
    <other_name>AZA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnoised with acute myeloid leukemia&#xD;
&#xD;
          2. Meet the criteria of the 2016 WHO classification system(APL were excluded), based on&#xD;
             blood cell counting, bone marrow biopsy, and cytogeneic diagnosis&#xD;
&#xD;
          3. Volunteered to sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mental disorders or other conditions that cannot meet the requirements of research,&#xD;
             treatment and monitoring&#xD;
&#xD;
          2. Uncontrolled cardiovascular disease&#xD;
&#xD;
          3. Allergic to azacytarine, homoharringtonie, or other drugs of this study&#xD;
&#xD;
          4. Any other conditions considered by the study investgators that are not suitable for&#xD;
             participating in this clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zheng Ge, M.D, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Medical School of South East University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zheng Ge, M.D, Ph.D</last_name>
    <phone>02583262468</phone>
    <phone_ext>02583262468</phone_ext>
    <email>Janege879@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology, Zhongda Hospital, Medical School of Southeast University</name>
      <address>
        <city>NanJing</city>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zheng o Ge, MD,PhD</last_name>
      <phone>02583262468</phone>
      <phone_ext>02583262468</phone_ext>
      <email>Janege879@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhongda Hospital</investigator_affiliation>
    <investigator_full_name>Ge Zheng</investigator_full_name>
    <investigator_title>Director of Department of Hematology</investigator_title>
  </responsible_party>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>Homoharringtonie</keyword>
  <keyword>Azacitidine</keyword>
  <keyword>Demethylation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Homoharringtonine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

